Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl. Cyprium is also obligated to pay 20% of ...

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago. These ...

Key market opportunities in healthcare finance solutions include increasing outpatient care, fintech integration, demand for flexible financing, adoption of predictive analytics, and growing chronic ...

Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The European Directory of Biotechnology Companies offers key market opportunities by providing access to 2,000 biotech companies and 5,000 executives. It assists in pinpointing decision-makers, ...

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, ...

Kane Biotech Inc. (TSX- V:KNE) ('Kane Biotech” or 'Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel in the International Wound Journal. The article 'Wound Healing ...

AI search is fundamentally changing how consumers navigate decision making, and brands must adapt in order to be discoverable.

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.